7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,079.50

-34.00

-0.83%

75,925.63

-85.71

-0.11%

Crude Oil Dec 26

90.34

-0.18

-0.20%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

Cingulate Inc. (CINGW)

0.0014 +0.0001 (+7.69%)

At close: November 6 at 12:20:13 PM EST

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

GlobeNewswire 4mo ago

CING

CINGW
+7.69%
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

GlobeNewswire 1mo ago

CING
CING: Second Quarter Results

Zacks Small Cap Research 2mo ago

CING
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

GlobeNewswire 2mo ago

CING
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

GlobeNewswire 2mo ago

CING
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

GlobeNewswire 3mo ago

CING
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

GlobeNewswire 4mo ago

CING
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

TMX Newsfile 5mo ago

CING
Cingulate Receives Complete Response Letter from FDA for CTx-1301

GlobeNewswire 5mo ago

CING
CING: Building Its Cash Position

Zacks Small Cap Research 5mo ago

CING
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

GlobeNewswire 5mo ago

CING
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever

Insider Monkey 6mo ago

CING

Mobilize your Website

View Site in Mobile | Classic

Share by: